Report
BioNTech SE : Omicron, an opportunity or risk for vaccine manufacturers?
>Vaccines might be less efficacious in preventing infections - Omicron alone carries 32 mutations in the spike protein, the relevant protein on the surface of the virus, helping it to enter human cells, vs the wild-type Wuhan strain. This is the protein against which all currently approved vaccines in the developed world are directed. There are also anecdotal reports about more infections happening with Omicron in vaccinated people. BioNTech CEO Ugur Sahin commented o...
Underlying
BioNTech SE
Provider
Oddo BHF
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Martial Descoutures
Other Reports on these Companies
Other Reports from Oddo BHF
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.